58.47  0 (0%)		09-16 16:00
Open: 58.835 High: 59.17 Volume: 2,157,600		Pre. Close: 58.47 Low: 58.28 Market Cap: 25,918(M)

Short term
Mid term
Targets	6-month :	72.08	1-year :	75.19
Resists	First :	61.72	Second :	64.37
Pivot price	60.91
Supports	First :	57.41	Second :	47.77
MAs	MA(5) :	58.67	MA(20) :	61.04
	MA(100) :	56.21	MA(250) :	46.99
MACD	MACD :	-0.1	Signal :	0.5
%K %D	K(14,3) :	13.7	D(3) :	11.3
RSI	RSI(14): 41.9
52-week	High :	64.37	Low :	33.97

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ RPRX ] has closed above bottom band by 17.3%. Bollinger Bands are 72.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	59.22 - 59.64	59.64 - 59.96
Low:	57.49 - 57.94	57.94 - 58.29
Close:	57.9 - 58.58	58.58 - 59.11

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Tue, 15 Sep 2026
A $7.5 million gift will help develop new blood cancer treatments - Stock Titan

Tue, 15 Sep 2026
California State Teachers Retirement System Decreases Stake in Royalty Pharma PLC $RPRX - MarketBeat

Mon, 14 Sep 2026
RPRX: Early target achievement and global expansion fuel strong growth and innovation in royalty funding - TradingView

Mon, 14 Sep 2026
WINTON GROUP Ltd Invests $1.28 Million in Royalty Pharma PLC $RPRX - MarketBeat

Sun, 13 Sep 2026
Royalty Pharma PLC $RPRX Shares Sold by National Pension Service - MarketBeat

Thu, 10 Sep 2026
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure? - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Shares Out	445 (M)
Shares Float	416 (M)
Held by Insiders	6.4 (%)
Held by Institutions	87.5 (%)
Shares Short	11,610 (K)
Shares Short P.Month	12,130 (K)

EPS	1.86
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	15.32
Profit Margin	32 %
Operating Margin	19.7 %
Return on Assets (ttm)	5 %
Return on Equity (ttm)	13.9 %
Qtrly Rev. Growth	16.5 %
Gross Profit (p.s.)	5.45
Sales Per Share	5.7
EBITDA (p.s.)	3.5
Qtrly Earnings Growth	-46.3 %
Operating Cash Flow	2,980 (M)
Levered Free Cash Flow	-1,200 (M)

PE Ratio	31.43
PEG Ratio	1.4
Price to Book value	3.81
Price to Sales	10.25
Price to Cash Flow	8.73

Dividend	0.23
Forward Dividend	0
Dividend Yield	0.3%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.